Avalo Therapeutics Inc expected to post a loss of $1.09 a share - Earnings Preview

Avalo Therapeutics

04/11/2022 17:08

* Avalo Therapeutics Inc  AVTX.OQ   AVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on November 7
(estimated). 
    * The Rockville Maryland-based  company is expected to
report  a
20.2% decrease in revenue to $1.078 million from $1.35 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Avalo Therapeutics
Inc is
for a loss of $1.09 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Avalo
Therapeutics Inc is $17​, above​ its last closing price
of $6.86. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -1.76       -1.77      -1.38     Beat    22
 Mar. 31 2022  -1.55       -1.60      -2.40     Missed  -50
 Dec. 31 2021  -1.75       -1.90      -1.92     Missed  -1.3​
 Sep. 30 2021  -2.19       -2.16      -2.04     Beat    5.6
 ​​Jun.        -2.09       -2.04      -2.16     Missed  -5.9
 30 2021                                                
 Mar. 31 2021  -2.47       -2.32      -3.84     Missed  -65.5​
 Dec. 31 2020  -1.80       -1.80      -2.16     Missed  -20
 Sep. 30 2020  -1.44       -1.14      -2.04     Missed  -78.9
 This summary was machine generated November 4 at 17:07 GMT.  All
figures in US dollars  unless otherwise stated